Delcath Systems, Inc. (DCTH) fair value analysis
Nasdaq · Updated 2026-10-19
DCTH price how computed
Valuation status
No fair-value estimate yetDCTH has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for DCTH yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $14.08
- Sector
- Healthcare
- 12-month range
- $8.19–$17.36
- Market cap
- $489M
- From 52-week high
- -18.9%
- Shares outstanding
- 34.7M
- Rank in Healthcare by quality score
- #2 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Delcath Systems, Inc. is a medical device company that develops and commercializes catheter-based technologies for the treatment of liver cancer and other cancers. The company operates primarily in the United States and Europe.
DCTH currently ranks #2 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $489M
- P/E (trailing)
- 1408x
- Revenue (TTM)
- $95.4M
- Net margin
- 0.6%
- EPS (TTM)
- $0.01
- Gross margin
- 89.8%
- Debt / equity
- 0.02
- Revenue growth (3-yr avg)
- 2204.2%
- Shares outstanding
- 34.7M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 31 · neutral
- 50-day average
- $16.11
- 200-day average
- $12.13
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+143.8%)
2026-03 ▲ beat (+66.7%)
2025-12 ▲ beat (+16.7%)
2025-09 ▲ beat (+122.2%)
2025-06 ▲ beat (+133.3%)
2025-03 ▲ beat (+15.4%)
2024-12 ▼ miss (-1200.0%)
2024-09 ▲ beat (+131.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $24
- Target vs last price
- +70.5%
What our data shows for DCTH
- Shares are trading in the middle of their 12-month price range of $8.19–$17.36.
- The 14-day relative strength index sits at a neutral 31.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- DCTH's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the DCTH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for DCTH show a shift in the 50/200-day trend state from uptrend to mixed this week. The stock's intermediate-term momentum signals have become less clearly directional as the shorter-term trend has diverged from the longer-term trajectory. The valuation verdict remains under review pending completion of the full valuation assessment.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is DCTH stock undervalued?
TickrTrends has no fair-value estimate for DCTH yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is DCTH's TickrTrends verdict?
DCTH is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does DCTH compare to other Healthcare stocks?
DCTH ranks #2 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is DCTH overbought or oversold?
DCTH's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does DCTH report earnings next?
DCTH's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does DCTH usually beat earnings estimates?
Over its last 8 reported quarters DCTH beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about DCTH?
Of 5 analysts covering DCTH, 5 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $24 (+70.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.